ANAB - AnaptysBio Stock Price, News & Analysis

$78.18 -1.05 (-1.33 %)
(As of 11/24/2017 09:58 AM ET)
Previous Close$79.23
Today's Range$77.30 - $81.85
52-Week Range$15.17 - $81.85
Volume203,700 shs
Average Volume206,831 shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About AnaptysBio (NASDAQ:ANAB)

AnaptysBio logoAnaptysBio, Inc. is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ANAB
CUSIPN/A

Debt

Debt-to-Equity Ratio0.09%
Current Ratio10.77%
Quick Ratio10.77%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.68 million
Price / Sales110.15
Cash FlowN/A
Price / CashN/A
Book Value$4.31 per share
Price / Book18.14

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPSN/A
Net Income$-4,250,000.00
Net MarginsN/A
Return on Equity-39.38%
Return on Assets-24.95%

Miscellaneous

Employees49
Outstanding Shares23,500,000

Frequently Asked Questions for AnaptysBio (NASDAQ:ANAB)

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) announced its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.02. View AnaptysBio's Earnings History.

Where is AnaptysBio's stock going? Where will AnaptysBio's stock price be in 2017?

8 equities research analysts have issued 12-month price targets for AnaptysBio's stock. Their forecasts range from $69.00 to $115.00. On average, they anticipate AnaptysBio's stock price to reach $86.13 in the next year. View Analyst Ratings for AnaptysBio.

Who are some of AnaptysBio's key competitors?

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the folowing people:

  • Hamza Suria, President, Chief Executive Officer, Director (Age 40)
  • Dominic G. Piscitelli, Chief Financial Officer (Age 42)
  • Marco Londei M.D., Chief Medical Officer (Age 60)
  • Hollings C. Renton III, Lead Independent Director (Age 70)
  • Carol G. Gallagher, Independent Director (Age 52)
  • Nicholas B. Lydon Ph.D., Independent Director (Age 60)
  • John P. Schmid, Independent Director (Age 53)
  • James A. Schoeneck, Independent Director (Age 59)

When did AnaptysBio IPO?

(ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who owns AnaptysBio stock?

AnaptysBio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include CORMORANT ASSET MANAGEMENT, LLC (5.02%), Perceptive Advisors LLC (4.18%), Citadel Advisors LLC (2.48%), JPMorgan Chase & Co. (0.78%), VHCP Management II LLC (0.71%) and Artal Group S.A. (0.64%). Company insiders that own AnaptysBio stock include Healthcare Vii LP Frazier, Holdings A/S Novo, Nicholas Lydon and Ventures Vii L P Avalon. View Institutional Ownership Trends for AnaptysBio.

Who sold AnaptysBio stock? Who is selling AnaptysBio stock?

AnaptysBio's stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A. and Iguana Healthcare Management LLC. Company insiders that have sold AnaptysBio company stock in the last year include Holdings A/S Novo and Ventures Vii L P Avalon. View Insider Buying and Selling for AnaptysBio.

Who bought AnaptysBio stock? Who is buying AnaptysBio stock?

AnaptysBio's stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, VHCP Management II LLC, JPMorgan Chase & Co., Sphera Funds Management LTD., State of New Jersey Common Pension Fund D, Perceptive Advisors LLC, Bank of New York Mellon Corp and Schwab Charles Investment Management Inc.. Company insiders that have bought AnaptysBio stock in the last two years include Healthcare Vii LP Frazier and Nicholas Lydon. View Insider Buying and Selling for AnaptysBio.

How do I buy AnaptysBio stock?

Shares of AnaptysBio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AnaptysBio's stock price today?

One share of AnaptysBio stock can currently be purchased for approximately $78.18.

How big of a company is AnaptysBio?

AnaptysBio has a market capitalization of $1.84 billion and generates $16.68 million in revenue each year. AnaptysBio employs 49 workers across the globe.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]


MarketBeat Community Rating for AnaptysBio (ANAB)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  157
MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for AnaptysBio (NASDAQ:ANAB)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 8 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $86.13 (10.16% upside)

Consensus Price Target History for AnaptysBio (NASDAQ:ANAB)

Price Target History for AnaptysBio (NASDAQ:ANAB)

Analysts' Ratings History for AnaptysBio (NASDAQ:ANAB)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017SunTrust Banks, Inc.Initiated CoverageBuy -> Buy$115.00N/AView Rating Details
11/9/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$101.00N/AView Rating Details
11/7/2017WedbushReiterated RatingOutperform -> Positive$75.00 -> $82.00N/AView Rating Details
10/13/2017Stifel NicolausReiterated RatingBuy$35.00 -> $76.00N/AView Rating Details
10/11/2017Robert W. BairdSet Price TargetOutperform -> Buy$36.00 -> $69.00N/AView Rating Details
10/10/2017Royal Bank Of CanadaBoost Price TargetOutperform -> Outperform$40.00 -> $79.00N/AView Rating Details
10/10/2017Credit Suisse GroupBoost Price TargetOutperform$38.00 -> $85.00N/AView Rating Details
10/10/2017JMP SecuritiesBoost Price TargetOutperform$45.00 -> $82.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for AnaptysBio (NASDAQ:ANAB)

Earnings by Quarter for AnaptysBio (NASDAQ:ANAB)

Earnings History by Quarter for AnaptysBio (NASDAQ ANAB)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.47)($0.45)$2.78 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.42)($0.13)$3.45 million$7.00 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.18)($0.75)$1.63 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AnaptysBio (NASDAQ:ANAB)
2017 EPS Consensus Estimate: ($1.67)
2018 EPS Consensus Estimate: ($1.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.24)($0.24)($0.24)
Q2 20171($0.47)($0.47)($0.47)
Q3 20171($0.56)($0.56)($0.56)
Q4 20173($0.44)($0.35)($0.40)
Q1 20183($0.51)($0.24)($0.39)
Q2 20183($0.64)($0.33)($0.47)
Q3 20183($0.72)($0.37)($0.53)
Q4 20183($0.80)($0.40)($0.58)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AnaptysBio (NASDAQ:ANAB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AnaptysBio (NASDAQ ANAB)

Institutional Ownership Percentage: 73.05%
Insider Trades by Quarter for AnaptysBio (NASDAQ:ANAB)
Insider Trades by Quarter for AnaptysBio (NASDAQ:ANAB)

Insider Trades by Quarter for AnaptysBio (NASDAQ ANAB)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/21/2017Holdings A/S NovoMajor ShareholderSell356,300$21.10$7,517,930.00View SEC Filing  
8/15/2017Holdings A/S NovoMajor ShareholderSell178,600$21.16$3,779,176.00View SEC Filing  
8/7/2017Holdings A/S NovoMajor ShareholderSell491,294$21.12$10,376,129.28View SEC Filing  
8/3/2017Holdings A/S NovoMajor ShareholderSell70,706$23.31$1,648,156.86View SEC Filing  
7/26/2017Ventures Vii L P AvalonMajor ShareholderSell37,040$24.35$901,924.00View SEC Filing  
1/31/2017Healthcare Vii L.P. FrazierMajor ShareholderBuy400,000$15.00$6,000,000.00View SEC Filing  
1/31/2017Nicholas LydonDirectorBuy16,666$15.00$249,990.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AnaptysBio (NASDAQ ANAB)

Source:
DateHeadline
AnaptysBio (ANAB) and Nivalis Therapeutics (ALPN) Head-To-Head SurveyAnaptysBio (ANAB) and Nivalis Therapeutics (ALPN) Head-To-Head Survey
www.americanbankingnews.com - November 21 at 5:38 AM
AnaptysBio, Inc. (ANAB) Now Covered by Analysts at SunTrust Banks, Inc.AnaptysBio, Inc. (ANAB) Now Covered by Analysts at SunTrust Banks, Inc.
www.americanbankingnews.com - November 19 at 4:56 PM
Brokers Set Expectations for AnaptysBio, Inc.s FY2017 Earnings (ANAB)Brokers Set Expectations for AnaptysBio, Inc.'s FY2017 Earnings (ANAB)
www.americanbankingnews.com - November 17 at 9:44 PM
Wedbush Brokers Boost Earnings Estimates for AnaptysBio, Inc. (ANAB)Wedbush Brokers Boost Earnings Estimates for AnaptysBio, Inc. (ANAB)
www.americanbankingnews.com - November 13 at 3:58 AM
AnaptysBio, Inc. (ANAB) to Post FY2017 Earnings of ($1.65) Per Share, Jefferies Group ForecastsAnaptysBio, Inc. (ANAB) to Post FY2017 Earnings of ($1.65) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - November 13 at 3:58 AM
AnaptysBio, Inc. (ANAB) Given Consensus Rating of "Buy" by BrokeragesAnaptysBio, Inc. (ANAB) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 12 at 1:50 AM
AnaptysBio, Inc. (ANAB) Upgraded by Zacks Investment Research to "Hold"AnaptysBio, Inc. (ANAB) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - November 10 at 3:42 PM
Brokers Issue Forecasts for AnaptysBio, Inc.s FY2019 Earnings (ANAB)Brokers Issue Forecasts for AnaptysBio, Inc.'s FY2019 Earnings (ANAB)
www.americanbankingnews.com - November 9 at 3:40 PM
AnaptysBio, Inc. (ANAB) Rating Reiterated by WedbushAnaptysBio, Inc. (ANAB) Rating Reiterated by Wedbush
www.americanbankingnews.com - November 7 at 11:16 AM
AnaptysBio, Inc. (ANAB) Posts  Earnings ResultsAnaptysBio, Inc. (ANAB) Posts Earnings Results
www.americanbankingnews.com - November 7 at 11:15 AM
Anaptysbio (ANAB) Announces Positive ANB019 Top-line Phase 1 Clinical Trial ResultsAnaptysbio (ANAB) Announces Positive ANB019 Top-line Phase 1 Clinical Trial Results
www.streetinsider.com - November 7 at 2:57 AM
AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial ResultsAnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results
finance.yahoo.com - November 6 at 4:40 PM
AnaptysBio to Participate in Upcoming Investor ConferencesAnaptysBio to Participate in Upcoming Investor Conferences
finance.yahoo.com - October 31 at 5:08 PM
AnaptysBio, Inc. (ANAB) Receives Consensus Recommendation of "Buy" from AnalystsAnaptysBio, Inc. (ANAB) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 18 at 4:52 AM
Anaptysbio (ANAB) Prices 3M Share Common Offering at $68.50/ShAnaptysbio (ANAB) Prices 3M Share Common Offering at $68.50/Sh
www.streetinsider.com - October 14 at 8:46 PM
AnaptysBio, Inc. (ANAB) Receives Buy Rating from Stifel NicolausAnaptysBio, Inc. (ANAB) Receives Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - October 13 at 11:56 PM
AnaptysBio, Inc. (ANAB) Stock Rating Reaffirmed by WedbushAnaptysBio, Inc. (ANAB) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - October 13 at 11:20 PM
Q1 2018 EPS Estimates for AnaptysBio, Inc. (ANAB) Cut by AnalystQ1 2018 EPS Estimates for AnaptysBio, Inc. (ANAB) Cut by Analyst
www.americanbankingnews.com - October 13 at 11:10 AM
AnaptysBio Announces Pricing of Public OfferingAnaptysBio Announces Pricing of Public Offering
finance.yahoo.com - October 12 at 9:44 PM
Featured Company News - AnaptysBio Announces Positive Interim Data from Phase-2a Clinical Trial of ANB020 for Treating Atopic DermatitisFeatured Company News - AnaptysBio Announces Positive Interim Data from Phase-2a Clinical Trial of ANB020 for Treating Atopic Dermatitis
finance.yahoo.com - October 12 at 4:42 PM
AnaptysBio Reaches Analyst Target PriceAnaptysBio Reaches Analyst Target Price
www.nasdaq.com - October 11 at 5:25 PM
AnaptysBio Inc. (ANAB) Soared To A New High On Phase 2 Study ResultsAnaptysBio Inc. (ANAB) Soared To A New High On Phase 2 Study Results
www.rttnews.com - October 11 at 5:25 PM
AnaptysBio, Inc. (ANAB) Downgraded by Zacks Investment ResearchAnaptysBio, Inc. (ANAB) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 11 at 5:20 PM
AnaptysBios (ANAB) Positive Rating Reaffirmed at Robert W. BairdAnaptysBio's (ANAB) Positive Rating Reaffirmed at Robert W. Baird
www.americanbankingnews.com - October 11 at 10:18 AM
Royal Bank Of Canada Raises AnaptysBio, Inc. (ANAB) Price Target to $79.00Royal Bank Of Canada Raises AnaptysBio, Inc. (ANAB) Price Target to $79.00
www.americanbankingnews.com - October 10 at 7:04 PM
Credit Suisse Group Boosts AnaptysBio, Inc. (ANAB) Price Target to $85.00Credit Suisse Group Boosts AnaptysBio, Inc. (ANAB) Price Target to $85.00
www.americanbankingnews.com - October 10 at 7:04 PM
Pre-Open Movers 10/10: (KALV) (ANAB) (VICL) Higher; (JBL) (LLY) (AXTA) Lower (more...)Pre-Open Movers 10/10: (KALV) (ANAB) (VICL) Higher; (JBL) (LLY) (AXTA) Lower (more...)
www.streetinsider.com - October 10 at 5:13 PM
Why AnaptysBio Is One of Tuesday’s Top StocksWhy AnaptysBio Is One of Tuesday’s Top Stocks
247wallst.com - October 10 at 5:13 PM
AnaptysBio Inc. (ANAB) Has Soared To A New High On Phase 2 Study ResultsAnaptysBio Inc. (ANAB) Has Soared To A New High On Phase 2 Study Results
www.nasdaq.com - October 10 at 5:13 PM
AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic DermatitisAnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis
finance.yahoo.com - October 10 at 5:13 PM
Here's Why AnaptysBio Inc. Is Rocketing Higher TodayHere's Why AnaptysBio Inc. Is Rocketing Higher Today
finance.yahoo.com - October 10 at 5:13 PM
AnaptysBio Files Registration Statement for Proposed Public OfferingAnaptysBio Files Registration Statement for Proposed Public Offering
finance.yahoo.com - October 10 at 5:13 PM
This Biotech Hit Record High; Could Undercut Regeneron In EczemaThis Biotech Hit Record High; Could Undercut Regeneron In Eczema
finance.yahoo.com - October 10 at 5:13 PM
JMP Securities Raises AnaptysBio, Inc. (ANAB) Price Target to $82.00JMP Securities Raises AnaptysBio, Inc. (ANAB) Price Target to $82.00
www.americanbankingnews.com - October 10 at 4:34 PM
Head to Head Comparison: Omeros Corporation (OMER) versus AnaptysBio (ANAB)Head to Head Comparison: Omeros Corporation (OMER) versus AnaptysBio (ANAB)
www.americanbankingnews.com - October 7 at 4:18 AM
ETFs with exposure to AnaptysBio, Inc. : October 2, 2017ETFs with exposure to AnaptysBio, Inc. : October 2, 2017
finance.yahoo.com - October 2 at 3:43 PM
AnaptysBio, Inc. to Post FY2019 Earnings of ($2.78) Per Share, Wedbush Forecasts (ANAB)AnaptysBio, Inc. to Post FY2019 Earnings of ($2.78) Per Share, Wedbush Forecasts (ANAB)
www.americanbankingnews.com - September 27 at 4:36 PM
AnaptysBio, Inc. (ANAB) Given Consensus Recommendation of "Buy" by AnalystsAnaptysBio, Inc. (ANAB) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 23 at 4:38 PM
ETFs with exposure to AnaptysBio, Inc. : September 22, 2017ETFs with exposure to AnaptysBio, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 2:06 PM
AnaptysBio, Inc. (ANAB) Now Covered by Analysts at Royal Bank Of CanadaAnaptysBio, Inc. (ANAB) Now Covered by Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 10:36 PM
Stifel Nicolaus Reaffirms Buy Rating for AnaptysBio, Inc. (ANAB)Stifel Nicolaus Reaffirms Buy Rating for AnaptysBio, Inc. (ANAB)
www.americanbankingnews.com - September 12 at 12:00 PM
ETFs with exposure to AnaptysBio, Inc. : September 12, 2017ETFs with exposure to AnaptysBio, Inc. : September 12, 2017
finance.yahoo.com - September 12 at 1:22 AM
AnaptysBio, Inc. :ANAB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017AnaptysBio, Inc. :ANAB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017
finance.yahoo.com - September 8 at 4:15 PM
AnaptysBio, Inc. – Value Analysis (NASDAQ:ANAB) : September 2, 2017AnaptysBio, Inc. – Value Analysis (NASDAQ:ANAB) : September 2, 2017
finance.yahoo.com - September 2 at 2:29 AM
AnaptysBio, Inc. (ANAB) Given Consensus Recommendation of "Buy" by BrokeragesAnaptysBio, Inc. (ANAB) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 29 at 4:44 PM
AnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : August 29, 2017AnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : August 29, 2017
finance.yahoo.com - August 29 at 4:12 PM
AnaptysBio, Inc. (ANAB) Price Target Raised to $38.00 at Credit Suisse GroupAnaptysBio, Inc. (ANAB) Price Target Raised to $38.00 at Credit Suisse Group
www.americanbankingnews.com - August 25 at 12:28 PM
AnaptysBio Announces Appointment of J. Anthony Ware, M.D. to Board of DirectorsAnaptysBio Announces Appointment of J. Anthony Ware, M.D. to Board of Directors
finance.yahoo.com - August 24 at 3:50 PM
AnaptysBio, Inc. (ANAB) Major Shareholder Holdings A/S Novo Sells 356,300 SharesAnaptysBio, Inc. (ANAB) Major Shareholder Holdings A/S Novo Sells 356,300 Shares
www.americanbankingnews.com - August 21 at 7:26 PM
Holdings A/S Novo Sells 178,600 Shares of AnaptysBio, Inc. (ANAB) StockHoldings A/S Novo Sells 178,600 Shares of AnaptysBio, Inc. (ANAB) Stock
www.americanbankingnews.com - August 16 at 7:39 PM

Social Media

Financials

Financials are not available for this stock.

Chart

AnaptysBio (NASDAQ ANAB) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.